Cargando…
USP12 promotes CD4(+) T cell responses through deubiquitinating and stabilizing BCL10
Deubiquitinases (DUBs) regulate diverse biological processes and represent a novel class of drug targets. However, the biological function of only a small fraction of DUBs, especially in adaptive immune response regulation, is well-defined. In this study, we identified DUB ubiquitin-specific peptida...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481463/ https://www.ncbi.nlm.nih.gov/pubmed/33941870 http://dx.doi.org/10.1038/s41418-021-00787-y |
Sumario: | Deubiquitinases (DUBs) regulate diverse biological processes and represent a novel class of drug targets. However, the biological function of only a small fraction of DUBs, especially in adaptive immune response regulation, is well-defined. In this study, we identified DUB ubiquitin-specific peptidase 12 (USP12) as a critical regulator of CD4(+) T cell activation. USP12 plays an intrinsic role in promoting the CD4(+) T cell phenotype, including differentiation, activation, and proliferation. Although USP12-deficient CD4(+) T cells protected mice from autoimmune diseases, the immune response against bacterial infection was subdued. USP12 stabilized B cell lymphoma/leukemia 10 (BCL10) by deubiquitinating, and thereby activated the NF-κB signaling pathway. Interestingly, this USP12 regulatory mechanism was identified in CD4(+) T cells, but not in CD8(+) T cells. Our study results showed that USP12 activated CD4(+) T cell signaling, and targeting USP12 might help develop therapeutic interventions for treating inflammatory diseases or pathogen infections. |
---|